Quick Answer
Tempest Therapeutics, Inc. reported Stockholders Equity of $6.67 million for the year ending 2025.
- Tempest Therapeutics, Inc. showed a decrease of -65.1% in Stockholders Equity from 2024 to 2025.
- This data is from Tempest Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2012: -$8.02 million | Q3 2012: $34.41 million | Q2 2013: $54.41 million | Q3 2013: $49.00 million | Q1 2014: $86.40 million | Q2 2014: $78.70 million | Q3 2014: $68.63 million | Q1 2015: $169.09 million | Q2 2015: $156.71 million | Q3 2015: $142.59 million | Q1 2016: $108.84 million | Q2 2016: $146.56 million | Q3 2016: $129.88 million | Q1 2017: $94.72 million | Q2 2017: $81.14 million | Q3 2017: $72.29 million | Q1 2018: $57.33 million | Q2 2018: $50.21 million | Q3 2018: $44.91 million | Q1 2019: $61.52 million | Q2 2019: $52.97 million | Q3 2019: $43.07 million | Q1 2020: -$54.47 million | Q2 2020: -$59.37 million | Q3 2020: -$64.65 million | Q1 2021: -$73.95 million | Q2 2021: $48.11 million | Q3 2021: -$43.54 million | Q1 2022: $29.36 million | Q2 2022: $34.93 million | Q3 2022: $26.77 million | Q1 2023: $10.97 million | Q2 2023: $5.01 million | Q3 2023: -$1.19 million | Q1 2024: $20.63 million | Q2 2024: $16.94 million | Q3 2024: $11.46 million | Q1 2025: $11.13 million | Q2 2025: $9.78 million | Q3 2025: $6.35 million.
- Over the full 15 years of available data (2011 to 2025), Tempest Therapeutics, Inc.'s Stockholders Equity has grown by 380.5%.
- Historical annual values: Fiscal year 2025: $6.67 million | Fiscal year 2024: $19.13 million | Fiscal year 2023: $26.77 million | Fiscal year 2022: $18.11 million | Fiscal year 2021: $36.12 million | Fiscal year 2020: -$68.79 million | Fiscal year 2019: -$50.36 million | Fiscal year 2018: $70.95 million | Fiscal year 2017: -$130.69 million | Fiscal year 2016: $108.22 million | Fiscal year 2015: $126.85 million | Fiscal year 2014: $55.33 million | Fiscal year 2013: $41.70 million | Fiscal year 2012: $30.72 million | Fiscal year 2011: -$2.38 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: